JP2007512359A - 新規なリン含有甲状腺ホルモン様物質 - Google Patents

新規なリン含有甲状腺ホルモン様物質 Download PDF

Info

Publication number
JP2007512359A
JP2007512359A JP2006541569A JP2006541569A JP2007512359A JP 2007512359 A JP2007512359 A JP 2007512359A JP 2006541569 A JP2006541569 A JP 2006541569A JP 2006541569 A JP2006541569 A JP 2006541569A JP 2007512359 A JP2007512359 A JP 2007512359A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
aryl
substituted
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006541569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512359A5 (https=
Inventor
マーク・ディ・エライオン
ジャン・ホンジャン
セルジュ・アシュ・ボイエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of JP2007512359A publication Critical patent/JP2007512359A/ja
Publication of JP2007512359A5 publication Critical patent/JP2007512359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/306—Arylalkanephosphinic acids, e.g. Ar-(CH2)n-P(=X)(R)(XH), (X = O,S, Se; n>=1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4465—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006541569A 2003-11-19 2004-11-19 新規なリン含有甲状腺ホルモン様物質 Pending JP2007512359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52383003P 2003-11-19 2003-11-19
US59852404P 2004-08-03 2004-08-03
PCT/US2004/039024 WO2005051298A2 (en) 2003-11-19 2004-11-19 Novel phosphorus-containing thyromimetics

Publications (2)

Publication Number Publication Date
JP2007512359A true JP2007512359A (ja) 2007-05-17
JP2007512359A5 JP2007512359A5 (https=) 2011-09-22

Family

ID=34636490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541569A Pending JP2007512359A (ja) 2003-11-19 2004-11-19 新規なリン含有甲状腺ホルモン様物質

Country Status (10)

Country Link
US (3) US7829552B2 (https=)
EP (2) EP1689383B1 (https=)
JP (1) JP2007512359A (https=)
KR (1) KR20060109926A (https=)
CN (1) CN1882327A (https=)
AU (1) AU2004293013B2 (https=)
BR (1) BRPI0416639A (https=)
CA (1) CA2546601A1 (https=)
RU (1) RU2422450C2 (https=)
WO (1) WO2005051298A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512325A (ja) * 2003-11-20 2007-05-17 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
JP2007513089A (ja) * 2003-11-20 2007-05-24 イーライ リリー アンド カンパニー ビタミン受容体調節剤
JP2011504505A (ja) * 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
JP4880473B2 (ja) * 2004-10-08 2012-02-22 壽製薬株式会社 ホスホン酸誘導体及び血中の高リン酸が関与する疾患の治療剤
JP2019516783A (ja) * 2016-04-22 2019-06-20 メタベイシス・セラピューティクス・インコーポレイテッド 甲状腺ホルモン受容体アゴニスト及びその使用
JP2019531346A (ja) * 2016-09-16 2019-10-31 バイキング・セラピューティクス・インコーポレイテッド 甲状腺関連副作用を低下させる方法
JP2021518403A (ja) * 2018-03-22 2021-08-02 バイキング・セラピューティクス・インコーポレイテッド 化合物の結晶形態及び化合物の結晶形態を生成する方法
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
EP1891080A2 (en) * 2005-05-26 2008-02-27 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
DK1919878T3 (da) 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0610322D0 (en) * 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
CA2685962A1 (en) * 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
EP2930512B1 (en) * 2007-11-02 2018-01-31 Metabolon, Inc. Biomarkers for fatty liver disease and methods using the same
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation
US8877816B2 (en) * 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
BRPI0905987A2 (pt) 2008-02-22 2015-06-30 Dow Global Technologies Inc Sistema de material para armazenamento de energia térmica, método para fabricar um sistema de material para armazenamento de energia térmica e uso de um sistema de material para armazenamento de energia térmica
JP2011527740A (ja) * 2008-02-22 2011-11-04 ダウ グローバル テクノロジーズ エルエルシー 熱貯蔵デバイス
TW201004632A (en) * 2008-07-02 2010-02-01 Idenix Pharmaceuticals Inc Compounds and pharmaceutical compositions for the treatment of viral infections
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
EP2270021A1 (en) 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US8859098B2 (en) * 2012-05-18 2014-10-14 Lord Corporation Acrylic adhesion promoters
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
WO2014031441A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
EP2888005B1 (en) 2012-08-22 2019-04-03 Merck Sharp & Dohme Corp. Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
EP2888008B1 (en) 2012-08-22 2018-12-26 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydrofuran derivatives
WO2014031468A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014031445A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CN105188771A (zh) * 2013-03-15 2015-12-23 诺姆奥克塞斯公司 作为抗肥胖症剂的肌-肌醇三焦磷酸
CN110156838A (zh) * 2013-05-14 2019-08-23 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
HUE069048T2 (hu) * 2015-01-09 2025-02-28 Global Genomics Group Llc Vér alapú biomarkerek ateroszklerotikus koszorúér-betegség diagnosztizálására
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
BR112018071559B1 (pt) 2016-04-22 2024-02-06 Viking Therapeutics, Inc Uso de um agonista de receptor beta de hormônios da tireoide para o tratamento de adrenoleucodistrofia ligada ao x
CN107540725B (zh) * 2016-06-29 2020-04-07 孙青� 一种水溶性丹参酮ⅱa衍生物及其制备与应用
AU2018280118B2 (en) * 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CN107977505A (zh) * 2017-11-28 2018-05-01 兰州大学 一种前期降水衰退系数k确定的新方法
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
CN113365637A (zh) * 2018-12-05 2021-09-07 维京治疗公司 用于治疗肝部病症的组合物和方法
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2020118564A1 (en) * 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
AU2020334943A1 (en) 2019-08-19 2022-03-10 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
CN110672709B (zh) * 2019-11-18 2020-07-03 中国水产科学研究院黄海水产研究所 利用ea-irms分析海水中颗粒有机碳、氮稳定同位素的方法
US12466781B2 (en) 2019-11-29 2025-11-11 Autobahn Therapeutics, Inc. Thyromimetics
CN113336792B (zh) * 2020-02-18 2024-07-16 甘莱制药有限公司 一种环状膦酸酯化合物的制备方法
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
US20230257367A1 (en) 2020-06-02 2023-08-17 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone beta receptor agonist
WO2021257851A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
US12590072B2 (en) 2020-06-17 2026-03-31 Autobahn Therapeutics, Inc. Thyromimetics
CN114763363B (zh) * 2021-01-12 2024-10-01 上海喀露蓝科技有限公司 磷酸或磷酸酯类衍生物及其制备方法和其在医药上的用途
CN114907401A (zh) * 2021-02-08 2022-08-16 江苏天士力帝益药业有限公司 一种亚甲基双苯酚类磷配体衍生物，它们的制备与治疗用途
JP2025508746A (ja) * 2022-02-18 2025-04-10 バイキング・セラピューティクス・インコーポレイテッド 化合物の多形形態及び多形形態を生成する方法
CN115894554A (zh) * 2022-12-16 2023-04-04 烟台药物研究所 一种膦酸化合物的制备方法
AU2024216665A1 (en) * 2023-02-07 2025-08-07 Ascletis Pharma (China) Co., Limited Prodrugs of thyroid hormone analogs, methods of making and methods of using thereof
WO2024183772A1 (zh) * 2023-03-03 2024-09-12 浙江柏拉阿图医药科技有限公司 肝递送调节胆固醇代谢药物环状磷酸酯化合物及应用
WO2025162405A1 (zh) * 2024-02-01 2025-08-07 罗群 苯酚类衍生物及其医药用途
WO2026046097A1 (zh) * 2024-08-26 2026-03-05 歌礼制药(中国)有限公司 甲状腺素激素类的制剂及其制备方法
CN119192236B (zh) * 2024-11-27 2025-03-11 西北农林科技大学深圳研究院 一种丝氨酸水解酶抑制剂及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524489A (ja) * 1997-11-26 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
JP2002511084A (ja) * 1997-06-18 2002-04-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 選択性甲状腺ホルモン類似体
JP2002513422A (ja) * 1997-06-27 2002-05-08 カロ バイオ アクチェブラーグ 新規甲状腺レセプターリガンドおよび方法
JP2002540189A (ja) * 1999-03-29 2002-11-26 ノバルティス アクチエンゲゼルシャフト ジアリール誘導体およびその医薬としての使用

Family Cites Families (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485852A (en) 1958-11-13 1969-12-23 Syntex Corp 6-halo-6-dehydro-progesterones
US3120551A (en) * 1961-03-20 1964-02-04 Warner Lambert Pharmaceutical 5-(4-biphenylyl)-3-methylvaleric acid and functional derivatives thereof
DE1158966B (de) 1961-04-29 1963-12-12 Schering Ag Verfahren zur Herstellung von 6-Chlor-1, 2ª‡-methylen-í¸-17ª‡-hydroxyprogesteronestern
BE637389A (https=) 1962-09-13
US3357887A (en) * 1962-12-03 1967-12-12 Upjohn Co 4-phenoxy-3, 5-dihalophenylalkanols and hypocholesteremic compositions containing the same
FR1356282A (fr) 1963-01-09 1964-03-27 Nobel Bozel Procédé pour rendre rigides les cannelures de cartons ondulés
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
US3847988A (en) 1971-12-23 1974-11-12 Schering Corp Substituted imidates
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4069343A (en) * 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5612114B2 (https=) 1974-06-07 1981-03-18
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4069347A (en) * 1976-08-02 1978-01-17 Emery Industries, Inc. Compositions of quaternary ammonium derivatives of lanolin acids
JPS608117B2 (ja) 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
CA1121290A (en) 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4426453A (en) * 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
DE3037858A1 (de) * 1980-10-07 1982-05-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von reaktiven, kupplungsfaehigen derivaten der schilddruesenhormone t (pfeil abwaerts)3(pfeil abwaerts) und t (pfeil abwaerts)4(pfeil abwaerts) und deren verwendung
ES8207217A1 (es) 1980-10-09 1982-09-01 Hoechst Ag Procedimiento para la preparacion de un inactivador de alfa-amilasa
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US4554290A (en) * 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
FI844289L (fi) 1984-01-21 1985-07-22 Hoechst Ag Nya polypeptider med -amylashaemmande verkan, foerfarande foer deras framstaellning, deras anvaendning och farmaceutiska preparat.
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4673691A (en) * 1984-11-05 1987-06-16 Nicholas Bachynsky Human weight loss inducing method
ATE60571T1 (de) 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
DE3762617D1 (de) 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
US5041432A (en) 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
US5110940A (en) 1987-02-25 1992-05-05 Bristol-Myers Company Antihypercholesterolemic tetrazole compounds
DE3718638A1 (de) * 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4929600A (en) 1988-03-18 1990-05-29 University Of Deleware Endocrine manipulation to improve body composition of poultry
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5049696A (en) 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US4866058A (en) 1988-07-27 1989-09-12 Izydore Robert A Method for control of hyperlipidemia
IT1226726B (it) 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5196440A (en) 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
US5011947A (en) 1988-08-25 1991-04-30 Bristol-Myers Antihypercholesterolemic alkylene compounds
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5099035A (en) 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5166364A (en) 1989-02-27 1992-11-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
US5010105A (en) 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US4970221A (en) 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5106992A (en) 1989-07-28 1992-04-21 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5064856A (en) 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5025017A (en) 1989-09-28 1991-06-18 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5189180A (en) 1989-09-28 1993-02-23 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5217992A (en) 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
EP0421441B1 (en) 1989-10-06 1995-01-25 Fujirebio Inc. Pantothenic acid derivatives
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
IE903851A1 (en) 1989-11-03 1991-05-08 Boots Pharma Inc Iodothyronine polymers
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
EP0433983B1 (en) 1989-12-20 1998-03-04 Texas Instruments Incorporated Copper etch process using halides
IT1237793B (it) 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5049577A (en) 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
EP0466909B1 (en) 1990-02-05 1995-06-28 British Technology Group (Usa) Incorporated Thyroid hormone for cardiac treatment
US5158978A (en) 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
TW201738B (https=) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
GB9025509D0 (en) 1990-11-23 1991-01-09 Fujisawa Pharmaceutical Co New amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1992009572A1 (en) 1990-11-26 1992-06-11 Taisho Pharmaceutical Co., Ltd. Anilide derivative
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
ATE164063T1 (de) * 1991-12-30 1998-04-15 Akzo Nobel Nv Thyroaktive zusammensetzung mit kontrollierter freigabe
US5157134A (en) 1992-03-12 1992-10-20 E. R. Squibb & Sons, Inc. Dihydroxyheptanoic acids containing an oxabicycloheptane nucleus useful as antihypercholesterolemic agents
EP0567026B1 (en) 1992-04-20 2003-03-26 Takeda Chemical Industries, Ltd. 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DE69314718T2 (de) * 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CA2115183A1 (en) 1993-02-12 1994-08-13 Takashi Nomoto Substituted amic acid derivatives
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5491172A (en) 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
FR2705992B1 (fr) 1993-06-04 1995-07-21 Anastasie Maurice Gustave Euge Vitrage anti effractions.
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
JP3286745B2 (ja) 1993-09-10 2002-05-27 日清食品株式会社 シクロヘキサンジウレア誘導体及びその製法
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5519163A (en) * 1993-10-15 1996-05-21 Merck & Co., Inc. Inhibitors of phosphoinositide-specific phospholipase C
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
AU1942995A (en) 1994-03-15 1995-10-03 K.U. Leuven Research & Development New use of growth hormone
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GB9416219D0 (en) * 1994-08-11 1994-10-05 Karobio Ab Receptor ligands
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
JP3720395B2 (ja) 1994-09-20 2005-11-24 京都薬品工業株式会社 新規ヘテロ環誘導体、その製造方法およびその医薬用途
AU2453295A (en) 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
DE69521529T2 (de) * 1994-11-29 2001-10-11 Dainippon Pharmaceutical Co., Ltd. Indolderivat
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
DE19502209A1 (de) * 1995-01-25 1996-08-01 Hoechst Ag Phosphonoessigsäure-Derivate und deren Verwendung zur Behandlung von degenerativen Gelenkserkrankungen
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
DK0831769T3 (da) 1995-06-07 2004-02-23 Karobio Ab Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser
US6380255B1 (en) * 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
DK0832069T3 (da) 1995-06-07 2003-04-22 Pfizer Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
DE19534996A1 (de) 1995-09-21 1997-03-27 Bosch Gmbh Robert Verfahren zur Verbrennungsaussetzererkennung durch Auswertung von Drehzahlschwankungen
DK0866059T3 (da) 1995-10-05 2002-03-25 Kyoto Pharma Ind Nye heterocykliske derivater og medicinsk anvendelse deraf
FR2741619B1 (fr) 1995-11-28 1998-02-13 Pf Medicament Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
US6236946B1 (en) * 1995-12-13 2001-05-22 Thomas S. Scanlan Nuclear receptor ligands and ligand binding domains
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
JPH10195037A (ja) 1996-02-15 1998-07-28 Tanabe Seiyaku Co Ltd フェノール誘導体
US6361992B1 (en) * 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO1998007435A1 (en) * 1996-08-20 1998-02-26 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
CA2269807C (en) * 1996-10-24 2007-04-10 Novartis Ag Substituted aminoalkanephosphonic acids
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU2089297A (en) 1997-03-17 1998-10-12 Yun K. Tam Composition for prevention of hepatic steatosis
US5951989A (en) * 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
HUP0002294A3 (en) 1997-05-26 2001-10-29 Kowa Co Cyclic diamine compounds and medicines containing the same
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
HUP0003689A3 (en) 1997-09-05 2003-05-28 Warner Lambert Co Benzothiazine dioxide derivatives with endothelin antagonist activity, pharmaceutical compositions containing them and process for the preparation of known derivatives
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
KR20010033028A (ko) 1997-12-11 2001-04-25 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 막-관련 바이러스 복제의 억제
AU1623099A (en) 1997-12-22 1999-07-12 Alza Corporation Rate controlling membranes for controlled drug delivery devices
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
AU1937099A (en) 1997-12-31 1999-07-19 Alza Corporation Osmotic drug delivery monitoring system and method
EP1054588A4 (en) 1998-02-03 2002-09-25 Univ Maryland METHOD FOR STIMULATING THE PRODUCTION OF SPERM AND THE DEVELOPMENT OF OVARIES IN ANIMALS
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
WO1999047549A1 (en) 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DE69905877T2 (de) * 1998-06-02 2003-11-20 Arthromics Plc, Wilmslow Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
PA8471201A1 (es) 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
CA2335551C (en) * 1998-06-30 2009-03-03 The Regents Of The University Of California Thyroid hormone analogues and methods for their preparation
GB9816935D0 (en) * 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
KR100818845B1 (ko) 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
IL142807A0 (en) 1998-11-02 2002-03-10 Alza Corp Controlled delivery of active agents
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
ATE264333T1 (de) * 1999-02-23 2004-04-15 Ono Pharmaceutical Co Medikamente, die derivate der phosphorigensäure als aktiven inhaltsstoff enthalten
HK1044532A1 (zh) * 1999-03-01 2002-10-25 辉瑞产品公司 用作甲状腺受体配体的草氨酸及衍生物
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
PT1033364E (pt) * 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
US6790978B2 (en) * 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) * 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
CA2372079A1 (en) * 1999-05-05 2000-11-09 Aaron H. Leeman Novel catechols as antimicrobial agents
US6468755B1 (en) * 1999-08-10 2002-10-22 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
KR20020038741A (ko) 1999-08-27 2002-05-23 윌리암 엘. 레스페스 안드로겐 수용체 조절 화합물 및 방법
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
JP2003508397A (ja) 1999-08-27 2003-03-04 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲンレセプターモジュレーターとしての８−置換−６−トリフルオロメチル−９−ピリド［３，２−ｇ］キノリン化合物
AU7361400A (en) 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6787652B1 (en) * 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
US6627660B1 (en) * 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CA2392038A1 (en) 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
ES2242723T3 (es) 2000-02-17 2005-11-16 Bristol-Myers Squibb Company Ligandos derivados de anilina para el receptor de la tiroides .
US6852706B1 (en) * 2000-03-22 2005-02-08 The Wistar Institute Methods and compositions for healing heart wounds
DZ3276A1 (fr) 2000-03-31 2001-10-04 Pfizer Prod Inc Acides malonamiques et leurs derives, utiles comme ligands de recepteurs thyroidiens
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
WO2001079287A2 (en) 2000-04-17 2001-10-25 Sa Majesté La Reine Du Chef Du Canada - Agriculture Et Agroalimentaire Canada Steatosis-modulating factors and uses thereof
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
BR0110258A (pt) 2000-04-25 2003-01-07 Kyorin Seiyaku Kk Cristal estável de derivado de tiazolidinadiona e processo para sua produção
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
MXPA02012605A (es) 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
CN1440282A (zh) 2000-07-06 2003-09-03 德尔西斯药品公司 改善的甲状腺激素制剂
EP1299418A1 (en) 2000-07-10 2003-04-09 BTG INTERNATIONAL LIMITED (Company No. 2664412) Insulin derivatives and synthesis thereof
CN1466465A (zh) * 2000-08-01 2004-01-07 ��Ұ����ҩ��ʽ���� 肥胖或脂肪肝的预防或治疗药物
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
US6680340B2 (en) * 2000-08-21 2004-01-20 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
DE60137728D1 (de) 2000-08-24 2009-04-02 Univ Tennessee Res Foundation Selektive Modulatoren des Androgenrezeptors und Methoden zu deren Verwendung
DE10046029A1 (de) * 2000-09-18 2002-03-28 Bayer Ag Indazole
EP1320536A1 (en) 2000-09-27 2003-06-25 Ilex Oncology Research S.A. $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP1345895B1 (de) 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
EP1347959A1 (de) * 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
US6982348B2 (en) * 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
AU2002228317A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
US6534676B2 (en) * 2001-01-31 2003-03-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
JP2004531479A (ja) 2001-02-08 2004-10-14 カロ バイオ アクチェブラーグ 甲状腺受容体リガンドとしてのフェノキシ置換されたベンゾ縮合ヘテロアリール誘導体
US20020193440A1 (en) 2001-02-20 2002-12-19 Ritter Steven C. Liothyronine sodium and levothyroxine sodium combination
EP1368296A1 (en) 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators
DE10115408A1 (de) 2001-03-29 2002-10-02 Bayer Ag Benzofuran-Derivate
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
GB0111861D0 (en) * 2001-05-15 2001-07-04 Karobio Ab Novel compounds
FR2825926A1 (fr) * 2001-06-14 2002-12-20 Sod Conseils Rech Applic Derives d'imidazoles modulant les canaux sodiques
US20030022868A1 (en) 2001-06-25 2003-01-30 Dalton James T. Selective androgen receptor modulators and methods of use thereof
WO2003003013A1 (en) 2001-06-29 2003-01-09 University Of Massachusetts Non-nuclear effects of thyroid hormone
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003061557A2 (en) 2001-08-14 2003-07-31 King Pharmaceuticals, Inc. Levothyroxine pharmaceutical compositions, methods of making and methods of administration
EP1499578A2 (en) 2001-08-24 2005-01-26 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
AU2002333456B2 (en) 2001-08-31 2008-07-17 Sanofi-Aventis Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
ATE313325T1 (de) * 2001-09-26 2006-01-15 Pfizer Prod Inc Indolcaroboxylsäure als thyroidrezeptor-liganden
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1442028A4 (en) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
EP1471049A4 (en) 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
US7208481B2 (en) 2002-02-19 2007-04-24 Ilex Products, Inc. Aminodiphosphonate apolipoprotein E modulators
WO2003075835A2 (en) 2002-03-04 2003-09-18 Smithkline Beecham Corporation Compositions and methods for regulating thyroid hormone metabolism and cholesterol and lipid metabolism via the nuclear receptor car
DE60317330T2 (de) * 2002-03-25 2008-08-21 Applera Corp., Bedford Systeme und verfahren zum nachweis der funktion nukleärer rezeptoren unter verwendung von reporterenzymmutanten komplementierungen
GB0208384D0 (en) 2002-04-11 2002-05-22 Karobio Ab Novel compounds
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
EP1364962A1 (en) 2002-05-24 2003-11-26 Stichting tot bevordering van de wetenschap der Endocrinologie Use of monocarboxylate transporter proteins for thyroid hormone transport
BR0311843A (pt) 2002-06-15 2005-03-15 Enteromed Inc Métodos para prevenir, inibir, tratar ou reduzir esteatose hepática não- alcoólica em um animal e para prevenir o desenvolvimento e/ou a reversão do processo de nafld em um animal
US20040137441A1 (en) 2003-01-15 2004-07-15 Isis Pharmaceuticals Inc. Modulation of thyroid hormone receptor interactor 3 expression
BR0312503A (pt) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
GB0215978D0 (en) 2002-07-10 2002-08-21 Karobio Ab Novel compounds
AU2003268078A1 (en) 2002-08-10 2004-02-25 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
GB0219022D0 (en) 2002-08-15 2002-09-25 Karobio Ab Novel thyromimetic compounds
WO2004026097A2 (en) 2002-09-19 2004-04-01 First Circle Medical, Inc. Treatment of steatosis using hyperthermia
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
EP1565171A4 (en) * 2002-11-05 2010-06-30 Shire Llc PROGRESSIVE ABSORPTION OF MIXED FORMULATIONS OF THYROID HORMONES
ITMI20022777A1 (it) * 2002-12-27 2004-06-28 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
US20040142868A1 (en) * 2003-01-21 2004-07-22 Sleeman Mark W. Method of treating liver steatosis in a mammal
US20040176425A1 (en) 2003-01-24 2004-09-09 Washburn William N. Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
CA2517896A1 (en) 2003-03-05 2004-09-16 Zymogenetics, Inc. Use of thyroid-stimulating hormone to induce lipolysis
AU2003901813A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
WO2004103289A2 (en) 2003-05-14 2004-12-02 New York University Driverse thyroid hormone receptor antagonists and uses thereof
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
CA2535665A1 (en) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
US6952844B2 (en) 2003-08-27 2005-10-11 Danaher Thomas C Bed-tent
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
CA2539288C (en) 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
WO2005030198A1 (ja) 2003-09-26 2005-04-07 Chugai Seiyaku Kabushiki Kaisha 脂肪肝又は肝疾患を治療するための医薬組成物
CA2542776A1 (en) 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
CA2565966A1 (en) 2004-06-08 2005-12-29 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
EP1891080A2 (en) 2005-05-26 2008-02-27 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
WO2006128056A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
DK1919878T3 (da) 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511084A (ja) * 1997-06-18 2002-04-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 選択性甲状腺ホルモン類似体
JP2002513422A (ja) * 1997-06-27 2002-05-08 カロ バイオ アクチェブラーグ 新規甲状腺レセプターリガンドおよび方法
JP2001524489A (ja) * 1997-11-26 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
JP2002540189A (ja) * 1999-03-29 2002-11-26 ノバルティス アクチエンゲゼルシャフト ジアリール誘導体およびその医薬としての使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010060912; ＬＡＣＯＳＴＥ，Ａ．Ｍ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｓｉｓｉ　ａｎｄ　ｂｉｏｌｏｇｉｃａｌ　ｐｒｏｐａｒｔｉｅｓ　ｏｆ　ｔｈｅ　ｐｈｏｓｐｈｏｎｏ　ａｎａｌｏｇ　ｏｆ　ｔｈｙｒｏｘｉｎｅ' Ｃｏｍｐｔｅｓ　Ｒｅｎｄｕｓ　ｄｅｓ　Ｓｅａｎｃｅｓ　ｄｅ　ｌ'Ａｃａｄｅｍｉｅ　ｄｅｓ　Ｓｃｉｅｎｃｅｓ，　Ｓｅｒｉｅ　Ｄ：Ｓｃｉｅｎｃｅｓ　Ｎａｔｕｒｅｌｌｅｓ Ｖｏｌ．２６７，　Ｎｏ．２２, 1968, ｐ．１８９０-１８９２ *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512325A (ja) * 2003-11-20 2007-05-17 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
JP2007513089A (ja) * 2003-11-20 2007-05-24 イーライ リリー アンド カンパニー ビタミン受容体調節剤
JP4880473B2 (ja) * 2004-10-08 2012-02-22 壽製薬株式会社 ホスホン酸誘導体及び血中の高リン酸が関与する疾患の治療剤
JP2011504505A (ja) * 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
JP2019516783A (ja) * 2016-04-22 2019-06-20 メタベイシス・セラピューティクス・インコーポレイテッド 甲状腺ホルモン受容体アゴニスト及びその使用
JP2019531346A (ja) * 2016-09-16 2019-10-31 バイキング・セラピューティクス・インコーポレイテッド 甲状腺関連副作用を低下させる方法
JP2022174261A (ja) * 2016-09-16 2022-11-22 バイキング・セラピューティクス・インコーポレイテッド 甲状腺関連副作用を低下させる方法
JP7656574B2 (ja) 2016-09-16 2025-04-03 バイキング・セラピューティクス・インコーポレイテッド 甲状腺関連副作用を低下させる方法
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
JP2021518403A (ja) * 2018-03-22 2021-08-02 バイキング・セラピューティクス・インコーポレイテッド 化合物の結晶形態及び化合物の結晶形態を生成する方法
JP7845821B2 (ja) 2018-03-22 2026-04-14 バイキング・セラピューティクス・インコーポレイテッド 化合物の結晶形態及び化合物の結晶形態を生成する方法

Also Published As

Publication number Publication date
RU2422450C2 (ru) 2011-06-27
US7829552B2 (en) 2010-11-09
US20060046980A1 (en) 2006-03-02
RU2006117986A (ru) 2007-12-27
EP2428516A1 (en) 2012-03-14
US20100081634A1 (en) 2010-04-01
WO2005051298A3 (en) 2005-08-11
CA2546601A1 (en) 2005-06-09
WO2005051298A2 (en) 2005-06-09
US20090118236A1 (en) 2009-05-07
EP1689383A2 (en) 2006-08-16
AU2004293013A1 (en) 2005-06-09
CN1882327A (zh) 2006-12-20
BRPI0416639A (pt) 2007-01-16
AU2004293013B2 (en) 2011-04-28
EP1689383A4 (en) 2009-02-18
US7514419B2 (en) 2009-04-07
KR20060109926A (ko) 2006-10-23
EP1689383B1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
JP2007512359A (ja) 新規なリン含有甲状腺ホルモン様物質
AU2006249348B2 (en) Novel phosphinic acid-containing thyromimetics
US10925885B2 (en) Thyromimetics for the treatment of fatty liver diseases
JP2008545710A (ja) 新規リン含有甲状腺ホルモン様剤
WO2011038207A1 (en) Phosphorus-containing thyroid hormone receptor agonists and methods of use
CN101180097A (zh) 新型含次膦酸的拟甲状腺素药
HK1119709A (en) Novel phosphorus-containing thyromimetics
MXPA06004880A (en) Novel phosphorus-containing thyromimetics
WO2010093601A1 (en) Novel sulfonic acid-containing thyromimetics, and methods for their use
HK1119409A (en) Novel phosphinic acid-containing thyromimetics

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071120

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20100629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130205